What do we know about bleeding risk in patients with cancer?
Venous thromboembolism (VTE) is a well-recognized complication in patients with cancer, with an increase in risk by a...
Congress reports
COVID-19-associated coagulopathy and thrombosis in cancer
During the 11th ICTHIC, Marcel M Levi talked about COVID-19 thrombotic implications in patients with cancer. Here, we...
Cancer genetic alterations and risk of venous thromboembolism
During the 11th ICTHIC, Simon Mantha talked about the relationship between genetic cancer alteration and the risk of...
PODCAST. Drug-drug interactions: Implications for anticoagulation use in patients with cancer
Cancer patients have an increased risk of VTE by at least 12-fold, and cancer therapies increase the risk of VTE by a...
DEBATE: Should VTE treatment continue beyond six months? The evidence behind the decision to continue anticoagulation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
DEBATE: Should VTE treatment continue beyond 6 months? Evidence supporting anticoagulation discontinuation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
Evolving data on cardiovascular complications in cancer
During the 11th ICTHIC, Hugo Ten Cate talked about the evolving data on cardiovascular complications in cancer. Here,...
The impact of warfarin on overall survival in cancer patients with VTE
During the 11th ICTHIC, 2022, Jeffrey Zwicker talked about the impact of warfarin on overall survival (OS) in cancer...
Venus thromboembolism and risk stratification and hematological malignancies
In recent years, the incidence of venous thromboembolism (VTE) has been rising in patients with cancer. A Danish cohort...
Flash Interviews from the 11th ICTHIC – Part 2
Andrés J. Munoz Martin: What are the main take-home messages from “Mortality impact of cancer-associated venous...